1. Introduction
1.1 General Study assumptions and Limitations
1.2 Market Definition
1.3 Study Scope
2. Research Methodology
2.1 Analyst Tools and Models
2.2 Research Flow
2.3 Research Data (Primary and Secondary)
3. Executive Summary
4. Market Overview
4.1 Market/Industry at a glance
4.2 Market Drivers
4.2.1 High prevalence of infectious diseases
4.2.2 Increasing government and non-government investments for vaccines Development.
4.2.3 Rising focus on Immunization
4.3 Market Restraints
4.3.1 High cost
4.3.2 Longer timelines required to produce the vaccines
4.4 Market Opportunities
4.4.1 Development of Low-cost vaccines
4.4.2 Use of adjuvants in vaccines
4.4.3 High growth prospects in emerging countries
5. Porters Five Force Analysis
5.1 Bargaining Power of Suppliers
5.2 Bargaining Power of Consumers
5.3 Threat of New Entrants
5.4 Threat of Substitute Products and Services
5.5 Competitive Rivalry within the industry
6. Vaccine Market Segmentation
6.1 By Technology
6.1.1 Live Attenuated Vaccines
6.1.2 Conjugate Vaccines
6.1.3 Recombinant Vaccines
6.1.4 Inactivated and Subunit vaccines
6.1.5 Toxoid Vaccines
6.1.6 Others
6.2 By Type
6.2.1 Monovalent Vaccines
6.2.2 Multivalent Vaccines
6.2.3 Others
6.3 By Disease Indication
6.3.1 Influenza
6.3.2 Pneumococcal Disease
6.3.3 Hepatitis
6.3.4 Polio
6.3.5 Meningococcal Disease
6.3.6 HPV (Human Papilloma Virus)
6.3.7 Rotavirus
6.3.8 Varicella
6.3.9 Dengue
6.3.10 Others
6.4 By Region
6.4.1 North America
6.4.1.1 United States
6.4.1.2 Canada
6.4.1.3 Rest of North America
6.4.2 Asia-Pacific
6.4.2.1 China
6.4.2.2 India
6.4.2.3 Japan
6.4.2.4 Rest of Asia-Pacific
6.4.3 Europe
6.4.3.1 Germany
6.4.3.2 United Kingdom
6.4.3.3 France
6.4.3.4 Rest of Europe
6.4.4 Latin America
6.4.4.1 Brazil
6.4.4.2 Argentina
6.4.4.3 Mexico
6.4.4.4 Rest of Latin America
6.4.5 Middle East &Africa
6.4.5.1 United Arab Emirates
6.4.5.2 South Africa
6.4.5.3 Saudi Arabia
6.4.5.4 Rest of MEA
7. Competitive Landscape
7.1 Most Adopted Strategies
7.2 Most Active Companies
7.3 Market Share Analysis
8. Company Profiles
8.1 Pfizer, Inc.
8.2 Merck & Co., Inc.
8.3 GlaxoSmithKline Plc
8.4 Johnson & Johnson
8.5 Sanofi Pasteur
8.6 Emergent BioSolutions Inc.
8.7 Astellas Pharma
8.8 Serum Institute of India
8.9 Mitsubishi Tanabe Pharma Corporation
8.10 CSL Limited
8.11 MedImmune, LLC
8.12 Panacea Biotec
8.13 AstraZeneca
8.14 Novavax AB
8.15 Others
9. Future outlook of the market
10. Disclaimer
